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Abstract: 
 
Two new xanthones identified as 15-chlorotajixanthone hydrate (1) and 14-methoxytajixanthone 
(2) were isolated from an Emericella sp. strain 25379 along with shamixanthone (3) and 
tajixanthone hydrate (4). The stereostructures of 1 and 2 were elucidated by spectroscopic and 
molecular modeling methods. The absolute configuration at the stereogenic centers of 1 was 
established according to CD measurements. In the case of 2, however, the absolute configuration 
at C-20 and C-25 was designated as S and R, respectively, by Mosher ester methodology. 
Thereafter, the configuration at C-14 and C-15 of 2 was established as S and S, respectively by 
comparing the optical rotation and 1H–1H coupling constant experimental values with those 
obtained through molecular modeling calculations at DFT B3LYP/DGDZVP level of theory for 
diasteroisomers 2a–2d. The activation of the calmodulin-sensitive cAMP phosphodiesterase 
(PDE1) was inhibited in the presence of 1–4 in a concentration-dependent manner. The effect of 
compounds 2 (IC50 = 5.54 μM) and 4 (IC50 = 5.62 μM) was comparable with that of 
chlorpromazine (CPZ; IC50 = 7.26 μM), a well known CaM inhibitor used as a positive control. 
The inhibition mechanism of both compounds was competitive with respect to CaM according to 
a kinetic study. A docking analysis with 2 and 4 using the AutoDock 4.0 program revealed that 
they interacted with CaM in the same pocket as trifluoropiperazine (TFP). 
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The new xanthones 1 and 2 were isolated from an extract of the mycelium and culture broth 
of Emericella sp. strain 25379 along with two known compounds. The structures of 1 and 2 were 
elucidated by spectroscopic and molecular modeling methods. The activation of the CaM-
sensitive PDE1 was inhibited in the presence of all isolates. A docking analysis revealed that 
they interacted with CaM in the same pocket of TFP. 
 
 
 
Keywords: Emericella | 15-Chlorotajixanthone hydrate | 14-Methoxytajixanthone | 
Shamixanthone | Tajixanthone hydrate | Calmodulin | Docking 
 
Article: 
 
1. Introduction 
 
The genus Emericella, one of the anamorphus of Aspergillus,2 biosynthesizes a remarkable 
diversity of secondary metabolites with interesting biological properties thus representing 
potential leads for the developing of new pharmaceutical agents. For example, E. 
nidulans produces antitumor indole alkaloids, prenylated polyketides, benzophenones and 
xanthones.3 E. variecolor makes simple cytotoxic quinones,4 indole alkaloids with radical 
scavenging activity,5 neuritogenic and antimicrobial polyketides,6 sesterterpenes,7 as well as 
cytotoxic and antimicrobial xanthones.8, 9 E. quadrilineata has yielded some immunostimulant 
xanthones10 and tremorgenic alkaloids, while E. aurantiobrunnea some variecolin analogues 
which compete with macrophage inflammatory protein (MIP)-1α for binding to human CCR5 in 
a scintillation proximity assay.11 E. falconensis and E. fruticulosa produce polyketides that 
inhibit growth of HL60 human leukemia cells and possess antioxidant properties.12, 13, 14, 15 E. 
ungis generates depsides, depsidones and phthalides.16 E. heterothallica17, 18 and E. 
striata19 produce pitetrathiodioxopiperazines which inhibit histamine release and consequently 
show a remarkable potential as antiallergic agents. E. violacea produces biphenyl ether type 
metabolites20 and E. purpurea indole alkaloids,21 with E. rugulosa, E. nidulans, E. 
astellata and E. venezuelensis the only species that biosynthetize aflatoxins.22 
 
Within the scope of a program aiming at the discovery of novel calmodulin (CaM)-inhibitors 
useful as pesticide or drug leads,23, 24, 25 herein we report the structure elucidation and CaM-
inhibitor properties of two new tajixanthones analogs from a Emericella strain isolated from a 
coral species collected on the Mexican Pacific coast. In addition, to assess their putative binding 
mode with CaM, a docking analysis was performed. Calmodulin was selected as a molecular 
target considering its involvement in a variety of cell functions through the regulation of several 
CaM-dependent enzymes. Modulation of physiological targets of CaM by natural or synthetic 
compounds offers great possibilities for the discovery of new leads for the development of 
herbicide or therapeutically useful agents. Indeed certain antipsychotic, smooth muscle relaxants, 
α-adrenergic blocking, inmunostimulant and cytoprotective drugs, among others, inhibit CaM.25 
 
2. Results and discussion 
 
Two new xanthones, namely, 15-chlorotajixanthone hydrate (1) and 14-methoxytajixanthone (2) 
were isolated from an Emericella sp. strain 25379 along with the known compounds 
shamixanthone (3) and tajixanthone hydrate (4).9 The four natural products were obtained as 
yellow powders and exhibited UV absorptions at 317, 292, 261 and 249 nm suggesting a 
hydroxyxanthone chromophore.9  
 
 
 
Compound 1 had the molecular formula C25H27O6Cl which was deduced from the molecular ion 
in the HREIMS (458.1504, calcd 458.1496). The isotopic pattern in the mass spectrum, with a 
typical M/M + 2 ratio of approximately 100:35, revealed the presence of one chlorine atom in the 
molecule. The 1H and 13C NMR (Table 1) confirmed the tajixanthone type skeleton9 and were 
almost identical to those of compound 4, differing only in the chemical shifts of the signals of the 
isoprenyl side chain at C-4. Thus, the spectra of 1 exhibited signals for H-14a, H-14b/C-14 and 
H-15/C-15 at δH/δC 3.05, 3.13/28.6 and 3.03/63.4, respectively, rather than δH/δC 2.63, 3.02/32.0 
and 3.70/77.7 suggesting that the hydroxyl group at C-15 in 4 was replaced by a chlorine atom 
in 1. The substitution pattern along the xanthone and dihydropyran residues was corroborated by 
detailed analysis of the HMBC and NOESY spectra (Table 1). Biogenetic considerations, 
consistent NOESY correlations, and the close correspondence between the Cotton effects 
of 1 [Δε (nm) −2.27 × 104 (249), −2.08 × 104 (261), 1.48 × 104 (285), −1.30 × 104 (336)] and 
those of 4 [(Δε (nm) −1.24 × 105 (245), −8.62 × 104 (260), 3.21 × 104 (292), 
−4.36 × 104 (336 nm)] strongly supported that the absolute configuration at the stereogenic 
centers at C-15, C-20 and C-25 was identical in both compounds. 
 
Table 1. NMR data of 15-chlorotajixanthone hydrate (1) 
Position Compound 1 
δC δH, mult (J in Hz) HMBC NOESY 
1 160.5 
 
H-2, H-3 
 
2 137.1 7.53 d (8.0) H-14a, H-14b H-14a, H-14b 
3 119.3 6.80 d (8.0) H-2 
 
4 115.23 
 
H-3, H-14a, H-14b, H-15 
 
5 109.3 7.33 d (1.0) 
 
H-24 
6 138.6 
 
H-24 
 
7 149.6 
 
H-5, H-19a, H-19b, H-25, H-24 
 
8 119.3 
 
H-24 
 
9 109.3 
 
H-2 
 
10 152.1 
 
H-15, H-14a, H-14b 
 
11 152.0 
 
H-5 
 
12 121.1 
 
H-25, H-20 
 
13 184.4 
   
 
14 28.6 a 3.05 brd (16.6) H-2 H-2, H-17, H-18 
b 3.13 dd (8.0, 16.3)  
15 63.4 3.03 dd (2.0, 10.5) H-14a, H-14b, H-18, H-17 H-2, H-18 
16 116.9 
 
H-14a, H-14b, H-15 
 
17 24.8 1.34 s H-18 H-14 
18 19.0 1.46 s H-17 H-15, H-14  
19 64.6 a 4.44 ddd (1.0, 3.5, 
11.0) 
H-25 H-19b, H-20 
b 4.37 dd (3.0, 11.0) H-19a, H-20, H-23  
20 44.9 2.74 ddd (3.0, 3.0, 3.5) H-23, H-25, OH-25, H-19a, H-19b, H-22a, H-22b H-2 
21 142.6 
 
H-19a, H-19b, H-25 
 
 
22 112.3 a 4.82 ddd (0.5, 1.5, 2.5) H-23 H-22b, H-25 
b 4.60 dd (1.5, 2.5) H-22a, H-23  
23 22.5 1.87 t (0.5) H-22a, H-22b H-20 
24 17.4 2.37 d (1.0) H-5 
 
25 63.2 5.43 ddd (1.0, 3.0, 3.5) OH-25, H-19a, H-19b H-20, H-23, OH-25, 
H-22b 
OH-1 
 
12.66 d (0.5) 
  
OH-16 
 
2.47 s 
  
OH-25 
 
5.03 d (4.0) 
  
 
The HRFABMS analysis of 2 gave the molecular formula C26H28O7. The NMR data of 2 (Table 
2) indicated that it differed from 14-methoxytajixanthone-25-acetate (5) in the presence of a 
hydroxyl group at C-25 instead of an acetoxy group.9 Thus compared to 5, the methine signal for 
H-25 (δH 6.90, s) was diamagnetically shifted to δH 5.43 (d, J = 2.1 Hz) in the 1H NMR spectrum 
of 2. The position of the substituents in the molecule was also substantiated by careful 
examination of the HMBC and NOESY spectra (Table 2). The CD spectrum of 2, however, 
revealed some significant differences with respect to those of 1 and 4, which were attributed to 
the presence of the new chiral center at C-14. In order to establish the absolute configuration at 
the stereogenic centers in 2, a combination of molecular modeling calculations and advanced 
Mosher’s methodology was employed.26 Thus, analysis of the 1H NMR data (Table 2) of the (S)- 
and (R)-MTPA esters derivatives 2s and 2r prepared from 2, showed that ΔδH (S–R) for H-19a, 
H-19b and H-20 were +0.0037, +0.0025, and +0.0040, respectively. Therefore, the absolute 
configuration at C-20 and C-25 were established as S and R, respectively; this finding was in 
agreement with the stereochemistry at these centers for compounds 1, 3, 4 and other related 
xanthones.9 The configuration at C-14 and C-15 of 2 was next established by comparing the 
optical rotation and 1H–1H coupling constant experimental values with those obtained through 
molecular modeling calculations27, 28, 29 at DFT B3LYP/DGDZVP level of theory for 
diasteroisomers 2a–2d. Figure 1 displays the remarkable differences between the experimental 
optical rotation of 2 ([α]D = –38) and the calculated29 values for 2a, 2c and 2d, revealing that the 
(14S,15S,20S,25R)-stereoisomer (2b) represents the correct stereochemistry for 14-
methoxytajixanthone (2). The six more relevant conformers of this substance, including the 
global minimum 2b-1, are depicted in Figure 2. The free energies, equilibrium populations, 
coupling constants and [α]D values for the 28 more populated conformations of 2b are indicated 
in Table 3. Moreover, the agreement between the calculated and observed coupling 
constants J19a,20, J19b,20 and J20,25 confirmed the trans-relationship between the substituents at C-
20 and C-25 in the dihydropyran ring. 
 
Table 2. NMR data of 14-methoxy-tajixanthone (2), (S)-MTPA ester of 2 (2s), (R)-MTPA ester 
of 2 (2r), and Δδ value (δ2s-δ2r) in δ (ppm) 
Position Compound 2 2s 2r Δδ value 
δC δH, mult (J in Hz) HMBC NOESY δH δH (δ2s − δ2r) 
1 162.2 
 
H-2, H-3, OH-1, 
    
2 135.6 7.72 d (8.5) H-14a, H-14b, H-15 H-14a, H-14b, H-15 
   
3 119.0 6.88 d (8.5) H-2 
    
4 109.0 
 
H-3, H-14 
    
5 110.9 7.23 d (1.0) 
 
H-24 
   
6 138.9 
 
H-24 
    
7 149.8 
 
H-19a, H-19b, H-24 
    
8 119.1 
      
9 116.8 
 
H-3 
    
10 152.7 
 
H-2 
    
11 151.9 
 
H-5 
    
12 115.9 
      
13 184.4 
      
14 66.7 3.18 d (8.0) H-15 H-2, H-17, H-18 
   
15 76.1 4.67 d (8.0) H-2, H-14a, H-14b, H-17, 
H-18, CH3O-14 
H-2, H-18, CH3O-14 
   
16 56.9 
 
H-15, H-17, H-18, 
    
17 24.7 1.25 s H-18 
 
1.7952 1.7897 +0.0055 
18 19.8 1.32 s H-17 H-15, H-14 1.7523 1.7558 +0.0035 
19 64.7 a 4.43 dd (3.6, 10.8) 
 
H-25, H-23 4.4275 4.4238 +0.0037 
b 4.35 dd (3.0, 10.8) 4.3790 4.3765 +0.0025 
20 45.0 2.74 ddd (2.1, 3.0, 
3.6) 
H-19b, H-23, H-22a, H-22b H-25 2.7350 2.6950 +0.004 
21 142.5 
 
H-19b, H-23 
    
22 112.3 a 4.81 d (2.5) H-23 H-22b, H-25 4.8060 4.8045 +0.0015 
b 4.60 d (1.0) H-22a, H-23 4.6160 4.6145 +0.0015 
23 22.7 1.85 s H-22a, H-22b H-20 1.8391 1.9111 0.072 
24 17.5 2.36 s H-5 
 
2.3490 2.2860 +0.0063 
25 63.3 5.43 d (2.1) H-19a, H-19b H-20, H-23, H-22b 5.5025 5.4905 +0.012 
OH-1 
 
12.86 s 
     
CH3O-14 57.8 
      
OH-25 
 
4.94 brs 
     
 
Figure 1. Absolute differences between the experimental optical rotation of 14-
methoxytajixanthone (2) and the DFT B3LYP/DGDZVP calculated values for stereoisomers 2a–
2d. The small difference for (14S,15S)-2b allows the stereochemical assignment of 2. 
 
The effect of 1–4 on CaM was initially assessed with the CaM-sensitive cAMP 
phosphodiesterase (PDE1) assay which is commonly employed to detect CaM antagonists;23, 25, 30 
a human recombinant-CaM was employed as the activator. The results showed that the activation 
of PDE1 was inhibited in the presence of 2 and 4 in a concentration-dependent manner. The 
effect of compounds 2 (IC50 = 5.54 ± 1.28 μM) and 4 (IC50 = 5.62 ± 1.25 μM) was comparable to 
that of chlorpromazine (CPZ; IC50 = 7.26 ± 1.60 μM), a well known CaM inhibitor used as a 
positive control. A kinetic analysis31 using different amounts of CaM in the presence of different 
concentrations of 2 and 4 indicated that both xanthones acted as competitive antagonists of CaM, 
thus interfering with the formation of the CaM-PDE1 active complex. The estimated Ki 
(inhibition constant) values were 25.38 ± 2.26 and 13.92 ± 2.29 μM, respectively. 
 
The change of the electrophoretic behavior of CaM treated with the xanthones 1–4, as detected in 
a PAGE electrophoresis,32 provided an additional evidence of its interaction with the natural 
products. According to Figure 3, CaM treated with xanthones 1–4 has a lower electrophoretic 
mobility than the untreated protein. The best effect was observed with compounds 2 and 4. Upon 
conducting the same assay in the presence of EGTA, a calcium chelating agent, the mobility of 
CaM is not retarded indicating that the binding is Ca2+-dependent. 
 
 
Figure 2. The six more relevant conformations of 14-methoxytajixanthone (2) accounting for ca. 
90% of the conformational population. Substituents at the dihydropyran ring are pseudo-axial in 
structures 2b-1, 2b-2 and 2b-5 and pseudo-equatorial in 2b-3, 2b-4 and 2b-6. The 
conformational arrangement of the isoprene-derived chain remains essentially identical in these 
structures. 
 
Table 3. Free energies,a equilibrium populations,b coupling constants,c and specific rotation 
valuesd for conformers 1–28 of (14S,15S,20S,25R)-2 
Conformer ΔG P J19a,20 J19b,20 J20,25 J14,15 [α]D 
1 0.00 23.25 1.13 2.98 0.87 9.71 28.34 
2 0.03 22.12 1.37 2.44 0.96 9.71 174.63 
3 0.19 16.76 11.05 3.39 9.53 9.71 −179.00 
4 0.27 14.77 11.05 3.40 9.53 9.71 −176.04 
5 0.51 9.91 1.11 3.03 0.77 9.72 28.50 
6 1.26 2.79 11.15 3.57 9.03 9.71 −220.72 
7 1.47 1.95 1.36 2.46 0.95 9.60 21.38 
8 1.71 1.30 1.13 2.98 0.89 9.60 −134.48 
9 1.99 0.81 1.13 2.98 0.87 9.53 47.19 
Conformer ΔG P J19a,20 J19b,20 J20,25 J14,15 [α]D 
10 2.08 0.70 11.07 3.42 9.47 9.58 −307.80 
11 2.08 0.70 11.07 3.42 9.46 9.58 −307.77 
12 2.08 0.69 1.38 2.44 0.97 9.54 190.90 
13 2.09 0.68 1.13 2.97 0.89 1.96 234.91 
14 2.28 0.49 1.10 3.05 0.77 9.61 −116.56 
15 2.35 0.44 1.36 2.45 0.97 3.59 317.61 
16 2.35 0.44 11.05 3.39 9.54 9.56 −165.28 
17 2.38 0.42 11.05 3.40 9.54 9.56 −163.95 
18 2.51 0.34 1.11 3.04 0.77 9.53 40.98 
19 2.57 0.30 1.14 2.96 0.90 3.55 184.51 
20 2.57 0.30 1.10 3.07 0.78 1.97 221.75 
21 2.63 0.27 1.10 3.06 0.78 3.58 165.93 
22 2.94 0.16 11.17 3.60 8.99 9.59 −343.44 
23 3.11 0.12 11.15 3.57 9.05 9.55 −204.17 
24 3.21 0.10 11.06 3.41 9.50 3.60 −57.10 
25 3.55 0.06 1.35 2.48 0.94 9.56 −55.13 
26 3.55 0.06 1.13 2.99 0.87 9.57 −212.54 
27 3.66 0.05 11.04 3.39 9.49 9.59 −387.57 
28 4.08 0.02 1.10 3.06 0.76 9.57 −189.25         
Conformational averagee 4.86 3.01 4.06 9.54 −16.11 
Experimental 3.60 3.00 2.75 8.00 −38.00 
a B3LYP/DGDZVP, in kcal/mol. 
b Population percentages based on ΔG, assuming Boltzman statistics at T = 298.15 K and 1 atm. 
c Coupling constants in Hz calculated from B3LYP/DGDZVP dihedral angles using the Altona equation. 
d B3LYP/DGZVZP, specific rotation in degrees × [dm × g/cm3]−1. 
e Σi [α]Di, J–J19a,20i, J–J19b,20i, J–J20,25i or J–J14,15i × Pi, where [α]Di, J–J19a,20i, J–J19b,20i, J–J20,25i, J–J14,15i and Pi are 
values of [α]D, J–J19a,20, J–J19b,20, J–J20,25, J–J14,15 and population in percent for the ith conformation. 
 
 
Figure 3. PAGE CaM after treatment with compounds 1–4. Electrophoresis of 2 μg samples of 
CaM in the presence of 1 mM CaCl2. Pretreatment of the CaM samples, for 1.5 h at 30 °C: (A) 
no additions; (B) DMSO; (C) 0.033 μg/mL of CPZ; (D) 1; (E) 2; (F) 3; and (G) 4 isolates. In all 
cases 0.033 μg/mL of 1-4 in DMSO were applied. 
 
To assess the putative binding mode of compounds 1–4 with CaM, a docking analysis into the 
preferred CaM-binding pocket of trifluoropiperazine (TFP) was performed using the advanced 
docking program AutoDock 4.0.33 The docking protocol was validated for the CaM crystal 
structure (pdb code: 1a29) predicting the binding mode of TFP which was removed from the 
active site and docked back into pocket in the conformation found in its crystal 
structure.34 AutoDock successfully predicted the binding mode of TFP with a RMSD (root mean 
square deviation) of 1.837 Å (Fig. 4). Since CPZ was used as positive control in the assays, the 
procedure was also validated for this compound (RMSD = 1.931 Å; Fig. 4). The results of 
molecular docking study revealed that 1–4 interacted to the same pocket of TFP and CPZ (Table 
4 and Fig. 4). Furthermore, the overall correlation between the Ki and binding affinities predicted 
by AutoDock was good, in particular for compounds 2 and 4. The correlation coefficient 
(R2 = 0.971) between the Ki values of 2, 4 and CPZ and their AutoDock binding free energy 
values were excellent. 
 
 
Figure 4. Docking results obtained using AutoDock 4.0 inside the active site of CaM (blue, 
cartoons). (A) The docked TFP (yellow, ball and stick) and (B) CPZ ligands (grey, ball and 
stick) into CaM appear superimposed on the cocrystallized TPF (red, sticks). (C) Top ranked 
binding mode of the most populated cluster of 2 (green, sticks) and 4 (yellow, sticks) into the 
binding site. Compounds 2 and 4 attach to CaM at the same position than TFP (red, sticks). The 
metal atoms (Ca2+) are shown as pale-yellow color balls. Hydrogens are omitted for clarity. 
 
Table 4. AutoDock estimated docked energies, binding free energies (ΔGs), calculated and 
experimental inhibition constants (Ki), and experimental inhibitory concentrations (IC50) of 
compounds 1–4, CPZ and TFP 
Compound Docked energy (kcal/mol) ΔGs (kcal/mol) Ki (μM) (calculated) Ki (μM) (experimental) IC50 (μM) 
1 −4.81 −5.14 10.80 NDa 9.59 ± 2.65 
2 −8.15 −8.38 20.34 25.38 ± 2.26 5.54 ± 1.28 
3 −5.11 −5.63 5.77 NDa 29.16 ± 6.39 
4 −5.08 −4.54 14.36 13.92 ± 2.29 5.62 ± 1.25 
CPZ −6.85 −6.90 8.76 19.28 ± 2.54 7.26 ± 1.60 
TFP −10.06 −10.49 8.36 NDa NDa 
a Not calculated. 
 
In conclusion, the results of the present investigation indicated that Emericella sp. contains novel 
type of competitive CaM-inhibitors. According to AutoDock predictions these compounds 
interact with the protein at the same binding site of TFP, a well known CaM inhibitor. The CaM 
antagonist effect of 4 might be related with its mild cytotoxic9 action and other pharmacological 
properties yet to be discovered. As with E. variecolor and E. nidulans, the Emericella sp. strain 
25379 biosynthesizes tajixhantones type of compounds. 
 
3. Experimental 
 
3.1. General experimental procedures 
 
Optical rotations were obtained on a JASCO DIP 360 digital polarimeter. IR spectra were 
obtained using KBr disks on a Perkin-Elmer 599B spectrophotometer. The CD spectra of 1–
4 were obtained on a JASCO 720 spectropolarimeter at 25 °C in CHCl3 solution. UV spectra 
were recorded on a Shimadzu 160 UV spectrometer in CHCl3 solution. 1H, 13C and DEPT 
spectra including 2D NMR were recorded on a Varian Unity Plus 500 or on a Bruker DHX500 in 
CDCl3 spectrometers at 500 MHz (1H) or 125 MHz (13C) using tetramethylsilane (TMS) as an 
internal standard; chemical shifts were recorded as δ values. HREIMS was measured on a JEOL 
JMS-AX505HA mass spectrometer. Melting point determinations were determined using a 
Fisher-Johns apparatus and are uncorrected. Preparative HPLC was performed using a 
Symmetry® C18 column [silica gel, 4.6 × 250 mm, 5 μm, 0.6 mL/min]. Control of the equipment, 
data acquisition, processing, and management of chromatographic were performed by the 
Empoware® 2 software program (Waters). Open column chromatography: silica gel 60 (0.063–
0.200 mm), 70–230 Mesh (Merck). 
 
3.2. Fungal material 
 
Emericella sp. strain 25379 was isolated from the surface of a Coral collected at Marietas Islands 
in Puerto Vallarta, Jalisco, México, in 2006. Cultures of the fungus are maintained in the 
mycological collection of the Laboratorio de Micopatología, Instituto de Biología, UNAM. Stock 
cultures of the fungus were stored at 4 °C on agar plates of potato dextrose agar (PDA). In 
addition, subcultures were obtained in several culture media, such as PDA, PDA commercial, 
Czapek Yeast, among others. 
 
3.3. Fermentation and extraction 
 
Ten Fernbach flasks, each containing the liquid medium (2 L/flask) composed of Czapek 
concentrate (10 mL/L), K2HPO4 (1 g/L), powdered yeast extract (5 g/L) and sucrose (30 g/L) 
were individually inoculated with 1 cm2 agar plug taken from a stock culture. Flasks were 
cultures under static conditions at environmental temperature for 30 days. After incubation, the 
fermented whole broth (20 L) was filtered through cheese cloth to separate into supernatant and 
mycelia. The former was extracted exhaustively with CH2Cl2, and the CH2Cl2 solution was 
concentrated under reduced pressure to give a crude extract (1.5 g). The mycelium was 
macerated with CH2Cl2 (3 × 2 L). The combined organic phase was filtered over anhydrous 
Na2SO4 and concentrated in vacuo to give a dark brown solid (4.0 g). 
 
3.4. Isolation 
 
After evaporating the solvent in vacuo, the combined mycelia and culture (5.0 g) was 
fractionated by Si gel open CC with a hexane–CH2Cl2–EtOAc gradient, to yield 11 primary 
fractions (FI–FXI). From fraction FIX (90 mg), eluted with hexane–CH2Cl2–EtOAc (4:3.5:2.5), 
crystallized 18 mg of 4 as a yellow solid. Fraction FII (2 g), eluted with hexane–CH2Cl2–EtOAc 
(7:2:1), was subjected to Si gel CC (45 g) and eluted with a hexane–EtOAc gradient (1:0 → 0:1) 
to afford four fractions (FII-1–FII-4). Fraction FII-2 (70 mg) was further purified by TLC (CH2Cl2) 
to give 3 (15 mg). Fraction FIV (370 mg) was further fractionated on a Sephadex LH-20 
(Pharmacia) CC (MeOH) to yield seven secondary fractions (FIV-1–FIV-7). Shephadex fraction 
FIV-7 was resolved on a reverse phase HPLC column, eluting with ACN to yield 
compounds 1 (8 mg) and 2 (5 mg). 
 
3.4.1. 15-Chlorotajixanthone hydrate (1) 
 
Yellow needles, mp 180–181 °C; [α]D −4.0 (c 0.1, CHCl3); IR (KBr) νmax 3486, 3073, 2925, 
2849, 1736, 1644, 1567, 1240, 1022, and 920 cm−1; 1H, 13C, and 2D NMR data, see Table 1; 
HREIMS [M]+ m/z 458.1504 (calcd for C25H27O6Cl 458.1496); CD (CHCl3) (0.057 mg/mL) 
Δε (nm) −2.27 × 104 (249), −2.08 × 104 (261), 1.48 × 104 (285), −1.30 × 104 (336); 
UV λmax (CHCl3) log ε (nm) 3.60 (388), 3.25 (339), 3.76 (301), 3.72 (292), 4.07 (277), 3.96 
(258), 3.92 (249), 3.94 (244). 
 
3.4.2. 14-Methoxytajixanthone (2) 
 
Yellow needles, mp 200–201 °C; [α]D −38.0 (c 0.1, CHCl3); IR (KBr) νmax 3450, 3078, 2592, 
2887, 1795, and 920 cm−1; 1H, 13C, and 2D NMR data, see Table 2; HRFABMS 
[M+1]+ m/z 453.2074 (calcd for C26H28O7 453.2066); CD (CHCl3) (0.069 mg/mL) Δε (nm) 
−5.27 × 104 (247), −2.69 × 104 (260), −2.62 × 102 (295), −9.70 × 103 (301), 1.97 × 102 (317), 
−1.16 × 104 (335); UV λmax (CHCl3) log ε (nm) 3.23 (395), 2.59 (3.46), 2.48 (299), 3.42 (290), 
3.85 (277), 3.74 (261), 3.78 (254), 3.77 (248.5), 3.77 (245). 
 
3.4.3. Shamixanthone (3) 
 
Yellow needles, mp 141–143 °C; [α]D +34.1 (c 0.1, CHCl3) [lit. +16.0 (c 0.1, CHCl3)]; NMR 
spectral data were in agreement with those previously described in the literature;9 CD (CHCl3) 
(0.033 mg/mL) Δε (nm) −2.79 × 104 (263), 2.71 × 104 (295), −1.92 × 104 (336), 
1.16 × 104 (446); UV λmax (CHCl3) log ε (nm) 3.50 (395), 2.90 (346), 3.77 (299), 3.76 (293), 4.24 
(276), 4.05 (250), 4.07 (244). 
 
3.4.4. Tajixanthone hydrate (4) 
 
Yellow needles, mp 182–184 °C; [α]D −74.0 (c 0.1, CHCl3) [lit. −76.0 (c 0.23, CHCl3)]; NMR 
spectral data were in agreement with those previously described in the literature;9 CD (CHCl3) 
(0.025 mg/mL) Δε (nm) −1.24 × 105 (245), −8.62 × 104 (260), 3.21 × 104 (292), 
−4.36 × 104 (336); UV λmax (CHCl3) log ε (nm) 3.72 (397), 3.14 (347), 3.92 (299), 3.91 (294), 
4.42 (278), 4.25 (261), 4.25 (257), 4.21 (249), 4.24 (244). 
 
3.5. Phosphodiesterase activity 
 
The CaM used in this test was recombinant protein over-expressed following E. coli BL21-
A1™ One shot® vendor procedure (Invitrogen Corp. Carlsbad, CA). Cells BL21-AI were 
transformed with plasmids pET12-CALM1. Vector construction details will be published 
elsewhere. Briefly, the expression vector was constructed by amplifying CALM1 (human 
phosphorylase kinase, delta) gene by PCR from a cDNA clone pCMV6-XL5, obtained from 
OriGene (Origene Technology, Inc, Rockville, MD), and subcloned into vector pET12b 
Novagen (EMD Chemicals Inc., Darmstadt, Germany). After growth for 12 h, cells were 
harvested by centrifugation and subjected to CaM purification using phenyl-Sepharose CL4B as 
previously reported.35, 36, 37 Phosphodiesterase activity was measured according to the method 
described by Rivero et al.24 with some modifications. CaM (0.08 μg) was incubated with 
0.015 units of PDE1 from bovine brain during 30 min in 40 μL of assay solution containing 
0.063 units of 5′-nucleotidase (Crotalus atrox venom from Sigma), 45 mM Tris–HCl, 5.6 mM 
magnesium acetate, 45 mM imidazole, 2.5 mM calcium chloride and 10 μM BSA, pH 7.0. Test 
compounds were then added to the assay medium at 0.5, 1, 2, 3, 4, 7, 13, 20, 32, 50, and 65 μM 
in ACN-water (1:1), and the samples incubated during 30 min; thereafter 10 μL of 
10.8 mM cAMP was added to start the assay. After 15 min, the assay was stopped by the 
addition of 190 μL of malachite green solution. The amount of inorganic phosphate released, 
measured spectrophotometrically at 700 nm, correlated with the activity of the PDE1. The 
experiments to determine Ki values were performed as described above but in the presence of 
four different concentrations of CaM (25, 50, 100 and 200 ng/mL) and 10 μM BSA. All the 
results are expressed as the mean of at least six experiments ± SEM. The IC50 (concentration 
inhibiting by 50% the activity of the enzyme) values were determined by non-linear regression 
analysis by fitting to hyperbolic inhibition (Dixon plot31). The Ki was calculated from a global fit 
of data against inhibitor and CaM concentration using the simple competitive inhibition 
equation:ν=Vm[S]km+BSA1+[I]Ki+[S]Km+BSAwhere Vm = activity at saturating CaM 
concentration; Km = dissociation constant of CaM–PDE1 complex; I = concentration of the 
inhibitor and S = concentration of CaM; BSA = Bovine serum albumine. Non-linear regression 
was performed with the program Origin 7.0 (OriginLab Corporation, Northampton, MA). 
 
3.6. PAGE of compounds 1–4 with CaM 
 
The interaction of the isolated compounds with CaM was performed using nondenaturing 
homogeneous electrophoresis (PAGE). PAGE was performed according to previously described 
procedures using 12% polyacrylamide gels.32 Interaction of 1–4 with CaM was determined by 
observing the difference in electrophoretic mobility in two different conditions, in the presence 
of Ca2+ and in the presence of EGTA. The experimental conditions are described briefly in the 
legend of Figure 3. In each case the electrophoresis run was done in triplicate. CPZ was used as 
the positive control. 
 
3.7. Molecular modeling calculations 
 
A Monte Carlo conformational search27 for the structures 2a–2d was achieved by molecular 
mechanics using the MMFF94 force-field as implemented in the Spartan 04 program 
(Wavefunction Inc. Irvine, CA). In each case, the minimum energy structures were filtered, 
checked for duplicity and selected within an energy range between 0 and 3 kcal/mol to yield 30, 
28, 25, and 22 conformers for 2a–2d, respectively. Each conformer was optimized by DFT at the 
B3LYP/DGDZVP level of theory28 using Gaussian W03 (Gaussian Inc., Pittsburg, PA). The 
fully optimized structures were used to calculate the thermochemical parameters and the 
frequencies at 298 K and 1 atm. Calculations of the optical rotations29 were achieved at the same 
level of theory as well as the 1H–1H vicinal coupling constants. Both properties were Boltzmann-
weighted taking into account the DFT conformational population. No solvent effects were 
included in the calculations. 
 
3.8. Preparation of inhibitor structures 
 
The 3D structures of the studied compounds were constructed using Hyperchem 7.5 (HyperCube 
Inc., FL). Hydrogen atoms were added to the inhibitor structures. A geometry optimization was 
performed by applying the PM3 force field in Hyperchem 7.5. For all ligands, random starting 
positions, random orientations and torsions were used. This allowed searching for flexible 
conformations of the compounds during the docking process. 
 
3.9. Molecular docking 
 
The docking program AutoDock 4.0 was used to perform the automated molecular 
docking.33 The Lamarckian genetic algorithm (LGA) was applied to deal with the inhibitor–
enzyme interactions. The grid map with 60 × 60 × 60 points spaced equally at 0.375 Å was 
generated using the AutoGrid program to evaluate the binding energies between the compounds 
and the protein. Docking parameters were set to default values except for the number of GA runs 
(100), the energy evaluations (25,000,000), the maximum number of top individuals that 
automatically survive (0.1) and the step size for translation (0.2 Å). The docked inhibitor–
enzyme complexes were ranked according to the predicted binding energies and to the 
conformity to ideal geometry of the docked structures. 
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